Luvesilocin (RE104) FDA Breakthrough — Single-Dose Psychedelic for Postpartum Depression. MADRS 71.4% Remission, Ph3 2026

Standard postpartum depression treatment: SSRI 4~6 weeks, therapy months. What if single injection drops depression scores nearly half in 7 days? Reunion Neuroscience 2026.2.23 FDA Breakthrough Therapy Designation luvesilocin (RE104) — RECONNECT Ph2 demonstrates single-dose psychedelic pharmacological potential for postpartum depression.

Key Numbers

RECONNECT Ph2 results:

• 84 postpartum depression patients
• Design: 30mg vs 1.5mg (low-dose control) single dose
• MADRS Day 7: 30mg -23.0 vs 1.5mg -17.2 (p=0.0094)
• Remission: 30mg 71.4% vs 1.5mg 41.0%
• Response: 30mg 78.6% vs 1.5mg 53.7%
• Side effects: Transient hallucination·BP elevation (manageable)

Phase 3 Plan:

• 2026 initiation
• Global multisite
• Postpartum depression indication priority

What is Luvesilocin (RE104)

RE104 (Luvesilocin):

• New synthetic prodrug of 4-OH-DiPT (4-hydroxy-N,N-diisopropyltryptamine)
• 5-HT2A receptor partial agonist (psychedelic)
• IV injection
• Duration 2~4 hours (vs psilocybin 6~8 hours - shortened)
• Hallucination experience + concurrent psychotherapy

5-HT2A Psychedelic — New Depression Pharmacology

Existing depression drugs (SSRI):

• Serotonin reuptake blockade
• 4~6 wk onset
• Daily dosing
• 30~40% non-responders

5-HT2A Psychedelics:

• Direct 5-HT2A activation
• Explosive neuroplasticity (BDNF·synapse growth)
• Default Mode Network (DMN) restructure
• Single dose effect months

Postpartum-Specific Meaning

Why bigger potential postpartum:

• Mother SSRI aversion (breastmilk)
• Therapy time constraints
• Post-hormone-crash circuit instability → plasticity stimulation = big effect
• Single dose → temporary breastmilk pause·resume

RECONNECT Ph2 design meaning:

• Postpartum-specific (not general depression)
• Low-dose control (controlled psychedelic env = placebo control)
• 7-day timepoint (fast efficacy)

Hallucination Experience - Safety Management

Protocol:

• Clinical facility single injection
• Medical staff 4~6 hr companion
• Music·lighting env control
• Follow-up integration sessions

Contraindications:

• Psychosis·schizophrenia family hx
• Bipolar disorder
• Cardiovascular (BP elevation)

Korean Clinical Implications

Current Korea:

• Psychedelics = controlled drugs
• Clinical adoption undetermined
• Post US/EU approval review possible

Meaning:

• Global psychiatry paradigm shift (single-dose psychedelic circuit reset)
• Korean postpartum depression 27.3%
• Ethics·legal·access discussion needed

L70 New Dimension - Drug vs Stimulation vs Psychedelic

L66 Auvelity (AXS-05): NMDA depression (dextromethorphan + bupropion daily) L70 SAINT TMS: Drug-free brain stimulation 5 days L70 Luvesilocin (RE104): Single-dose psychedelic 5-HT2A direct activation

Three mechanisms same postpartum target. Drug·stimulation·psychedelic 3-axis precision psychiatry.

Psychedelic Depression Progress (Global)

Existing psychedelic trials:

• COMPASS COMP360 (psilocybin) Ph3
• MindMed MM-120 (LSD) Ph2/Ph3
• Atai LSD·DMT
• MAPS MDMA (PTSD) FDA rejected 2024

RE104 differentiator:

• Shortened duration (2~4h vs 6~8h)
• Postpartum-specific
• FDA Breakthrough

Concerns and Limits

Clinical:

• 84 small scale
• Long-term follow-up needed
• Single dose duration (3~6 mo?) TBD
• Repeat dosing safety TBD

Social:

• Psychedelic misuse risk
• Healthcare access gap
• Cost ($5,000~$10,000)
• Ethics guidelines TBD

Conclusion

Luvesilocin (RE104) FDA Breakthrough = single-dose psychedelic pharmacological new dimension for postpartum depression. RECONNECT Ph2 71.4% remission = faster·deeper than drugs possible. L70 = 35 pillars + brain stimulation + psychedelic. Drug·stimulation·psychedelic 3-axis targeting same postpartum depression via different mechanisms. Korea adoption post-global approval. Global psychiatry paradigm watch.